0

Close
 
Upcoming Allied Market Research
2023
Giardiasis Treatment Market

Giardiasis Treatment Market

by Drug Class (Amebicides, Anti-Helmintic, Others), by Drug Type (Branded, Generic) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A13360
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Giardiasis Treatment Market

Request Now !

Giardiasis is a type of protozoan infection and also termed as Beaver Fever. Giardiasis is disease condition caused by Giardia Duodenalis also known as G. lamblia and G. intestinalis. About 10% of population who got infected by giardiasis showed no symptoms. Moreover, this disease shows symptoms like diarrhea, abdominal pain, & weight loss. It is generally spread due to contaminated food & water. Giardiasis can be detected by diagnosis of stool samples. Primary condition of this disease can be cured without medication. Metronidazole, Tinidazole, Secnidazole, and Ornidazole are prescribed for treatment of giardiasis.  

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the giardiasis treatment market.

Top Impacting Factors

  • Rise in water pollution in developing countries, rise in consumption of unhygienic foods, lack of water treatment procedures in rural areas, rise in number of giardiasis diseases across the globe, and lack of sanitization practices are the key factors that drive the growth of the market.
  • In addition, ongoing research and development activities related to treatment of giardiasis disease, favourable reimbursement policies by governments, emerging modern healthcare technology in developing countries, rise in investment on developing infrastructures, private funding to launch effective diagnosis & treatment on giardiasis, and continuous strategic developments by key market players are expected to boost the growth of the market.
  • However, side effects related to use of anti-protozoan drugs and ignorance related to treatment of giardiasis can restrain the growth of the market.
  • Contrarily, government initiatives for spreading awareness for treatment of giardiasis and reoccurrence of giardiasis diseases are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2021, Lupin announced launch of Nitazoxanide 500mg tablet. It is a generic version of Alinia tablets and use in treatment of diarrhea caused due to Giardia lamblia in patients 12 years of age and above.

In 2018, Lupin announced its subsidiary company Symbiomix Therapeutics lunch of Solosec 2g granules. This product contain Secnidazole which is helpful in treatment of giardiasis.

Key Benefits of the Report

  • This study presents the analytical depiction of giardiasis treatment market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Giardiasis Treatment Market Report              

  • Which are the leading players active in the giardiasis treatment market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "giardiasis treatment"?
  • What is "giardiasis treatment" market prediction in the future?
  • Who are the leading global players in the "giardiasis treatment" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "giardiasis treatment" market report?

 Giardiasis Treatment Market Report Highlights

Aspects Details
By Drug Class
  • Amebicides
  • Anti-Helmintic
  • Others
By Drug Type
  • Branded
  • Generic
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Roxane Laboratories, Inc., Lupin Pharmaceuticals, Inc., Aurobindo Pharma Limited, F. Hoffmann-La Roche Ltd, Teva Pharmaceuticals, Heritage Pharmaceuticals Inc., Pfizer Inc., Baxter International Inc., Zydus Pharmaceuticals Inc., Abbott Laboratories
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: GIARDIASIS TREATMENT MARKET, BY DRUG CLASS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drug Class

    • 4.2. Amebicides

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Anti-Helmintic

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: GIARDIASIS TREATMENT MARKET, BY DRUG TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Drug Type

    • 5.2. Branded

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Generic

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: GIARDIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Retail Pharmacy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Online Pharmacy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: GIARDIASIS TREATMENT MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Drug Class

      • 7.2.3. Market Size and Forecast, By Drug Type

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Giardiasis Treatment Market

        • 7.2.6.1. Market Size and Forecast, By Drug Class
        • 7.2.6.2. Market Size and Forecast, By Drug Type
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Giardiasis Treatment Market

        • 7.2.7.1. Market Size and Forecast, By Drug Class
        • 7.2.7.2. Market Size and Forecast, By Drug Type
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Giardiasis Treatment Market

        • 7.2.8.1. Market Size and Forecast, By Drug Class
        • 7.2.8.2. Market Size and Forecast, By Drug Type
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Drug Class

      • 7.3.3. Market Size and Forecast, By Drug Type

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Giardiasis Treatment Market

        • 7.3.6.1. Market Size and Forecast, By Drug Class
        • 7.3.6.2. Market Size and Forecast, By Drug Type
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Giardiasis Treatment Market

        • 7.3.7.1. Market Size and Forecast, By Drug Class
        • 7.3.7.2. Market Size and Forecast, By Drug Type
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Giardiasis Treatment Market

        • 7.3.8.1. Market Size and Forecast, By Drug Class
        • 7.3.8.2. Market Size and Forecast, By Drug Type
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Giardiasis Treatment Market

        • 7.3.9.1. Market Size and Forecast, By Drug Class
        • 7.3.9.2. Market Size and Forecast, By Drug Type
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Giardiasis Treatment Market

        • 7.3.10.1. Market Size and Forecast, By Drug Class
        • 7.3.10.2. Market Size and Forecast, By Drug Type
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Giardiasis Treatment Market

        • 7.3.11.1. Market Size and Forecast, By Drug Class
        • 7.3.11.2. Market Size and Forecast, By Drug Type
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Giardiasis Treatment Market

        • 7.3.12.1. Market Size and Forecast, By Drug Class
        • 7.3.12.2. Market Size and Forecast, By Drug Type
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Drug Class

      • 7.4.3. Market Size and Forecast, By Drug Type

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Giardiasis Treatment Market

        • 7.4.6.1. Market Size and Forecast, By Drug Class
        • 7.4.6.2. Market Size and Forecast, By Drug Type
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Giardiasis Treatment Market

        • 7.4.7.1. Market Size and Forecast, By Drug Class
        • 7.4.7.2. Market Size and Forecast, By Drug Type
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Giardiasis Treatment Market

        • 7.4.8.1. Market Size and Forecast, By Drug Class
        • 7.4.8.2. Market Size and Forecast, By Drug Type
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Giardiasis Treatment Market

        • 7.4.9.1. Market Size and Forecast, By Drug Class
        • 7.4.9.2. Market Size and Forecast, By Drug Type
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Giardiasis Treatment Market

        • 7.4.10.1. Market Size and Forecast, By Drug Class
        • 7.4.10.2. Market Size and Forecast, By Drug Type
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Giardiasis Treatment Market

        • 7.4.11.1. Market Size and Forecast, By Drug Class
        • 7.4.11.2. Market Size and Forecast, By Drug Type
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Giardiasis Treatment Market

        • 7.4.12.1. Market Size and Forecast, By Drug Class
        • 7.4.12.2. Market Size and Forecast, By Drug Type
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Giardiasis Treatment Market

        • 7.4.13.1. Market Size and Forecast, By Drug Class
        • 7.4.13.2. Market Size and Forecast, By Drug Type
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Giardiasis Treatment Market

        • 7.4.14.1. Market Size and Forecast, By Drug Class
        • 7.4.14.2. Market Size and Forecast, By Drug Type
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Drug Class

      • 7.5.3. Market Size and Forecast, By Drug Type

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Giardiasis Treatment Market

        • 7.5.6.1. Market Size and Forecast, By Drug Class
        • 7.5.6.2. Market Size and Forecast, By Drug Type
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Giardiasis Treatment Market

        • 7.5.7.1. Market Size and Forecast, By Drug Class
        • 7.5.7.2. Market Size and Forecast, By Drug Type
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Giardiasis Treatment Market

        • 7.5.8.1. Market Size and Forecast, By Drug Class
        • 7.5.8.2. Market Size and Forecast, By Drug Type
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Giardiasis Treatment Market

        • 7.5.9.1. Market Size and Forecast, By Drug Class
        • 7.5.9.2. Market Size and Forecast, By Drug Type
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Giardiasis Treatment Market

        • 7.5.10.1. Market Size and Forecast, By Drug Class
        • 7.5.10.2. Market Size and Forecast, By Drug Type
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Giardiasis Treatment Market

        • 7.5.11.1. Market Size and Forecast, By Drug Class
        • 7.5.11.2. Market Size and Forecast, By Drug Type
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Pfizer Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Teva Pharmaceuticals

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Baxter International Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Zydus Pharmaceuticals Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Roxane Laboratories, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Heritage Pharmaceuticals Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Aurobindo Pharma Limited

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Lupin Pharmaceuticals, Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Abbott Laboratories

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. F. Hoffmann-La Roche Ltd

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL GIARDIASIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL GIARDIASIS TREATMENT MARKET FOR AMEBICIDES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL GIARDIASIS TREATMENT MARKET FOR ANTI-HELMINTIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL GIARDIASIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL GIARDIASIS TREATMENT MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL GIARDIASIS TREATMENT MARKET FOR BRANDED, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL GIARDIASIS TREATMENT MARKET FOR GENERIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL GIARDIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL GIARDIASIS TREATMENT MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL GIARDIASIS TREATMENT MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL GIARDIASIS TREATMENT MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL GIARDIASIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA GIARDIASIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. U.S. GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 18. U.S. GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. CANADA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 21. CANADA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE GIARDIASIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. FRANCE GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 31. FRANCE GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. ITALY GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 37. ITALY GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. ITALY GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. SPAIN GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 40. SPAIN GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. UK GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 43. UK GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 44. UK GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. RUSSIA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 46. RUSSIA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 47. RUSSIA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC GIARDIASIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. CHINA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 56. CHINA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. INDIA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 62. INDIA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. AUSTRALIA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. THAILAND GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 71. THAILAND GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 72. THAILAND GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. MALAYSIA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 74. MALAYSIA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 75. MALAYSIA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 76. INDONESIA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 77. INDONESIA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 78. INDONESIA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. REST OF ASIA PACIFIC GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 80. REST OF ASIA PACIFIC GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. LAMEA GIARDIASIS TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 83. LAMEA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 84. LAMEA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. BRAZIL GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 87. BRAZIL GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 88. BRAZIL GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH AFRICA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH AFRICA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 92. SAUDI ARABIA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 93. SAUDI ARABIA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 94. SAUDI ARABIA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. UAE GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 96. UAE GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 97. UAE GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 98. ARGENTINA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 99. ARGENTINA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 100. ARGENTINA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 101. REST OF LAMEA GIARDIASIS TREATMENT, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 102. REST OF LAMEA GIARDIASIS TREATMENT, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 103. REST OF LAMEA GIARDIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 104. PFIZER INC.: KEY EXECUTIVES
  • TABLE 105. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 106. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 107. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 108. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. TEVA PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 110. TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 111. TEVA PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 112. TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 113. TEVA PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
  • TABLE 115. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 116. BAXTER INTERNATIONAL INC.: OPERATING SEGMENTS
  • TABLE 117. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 118. BAXTER INTERNATIONAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. ZYDUS PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 120. ZYDUS PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 121. ZYDUS PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 122. ZYDUS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 123. ZYDUS PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. ROXANE LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 125. ROXANE LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 126. ROXANE LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 127. ROXANE LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 128. ROXANE LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 129. HERITAGE PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 130. HERITAGE PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 131. HERITAGE PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 132. HERITAGE PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 133. HERITAGE PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 134. AUROBINDO PHARMA LIMITED: KEY EXECUTIVES
  • TABLE 135. AUROBINDO PHARMA LIMITED: COMPANY SNAPSHOT
  • TABLE 136. AUROBINDO PHARMA LIMITED: OPERATING SEGMENTS
  • TABLE 137. AUROBINDO PHARMA LIMITED: PRODUCT PORTFOLIO
  • TABLE 138. AUROBINDO PHARMA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 139. LUPIN PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 140. LUPIN PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 141. LUPIN PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 142. LUPIN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 143. LUPIN PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 144. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 145. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 146. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 147. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 148. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 149. F. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
  • TABLE 150. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 151. F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
  • TABLE 152. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
  • TABLE 153. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL GIARDIASIS TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL GIARDIASIS TREATMENT MARKET
  • FIGURE 3. SEGMENTATION GIARDIASIS TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN GIARDIASIS TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALGIARDIASIS TREATMENT MARKET
  • FIGURE 11. GIARDIASIS TREATMENT MARKET SEGMENTATION, BY BY DRUG CLASS
  • FIGURE 12. GIARDIASIS TREATMENT MARKET FOR AMEBICIDES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. GIARDIASIS TREATMENT MARKET FOR ANTI-HELMINTIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. GIARDIASIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. GIARDIASIS TREATMENT MARKET SEGMENTATION, BY BY DRUG TYPE
  • FIGURE 16. GIARDIASIS TREATMENT MARKET FOR BRANDED, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. GIARDIASIS TREATMENT MARKET FOR GENERIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. GIARDIASIS TREATMENT MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 19. GIARDIASIS TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. GIARDIASIS TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. GIARDIASIS TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 26. COMPETITIVE DASHBOARD
  • FIGURE 27. COMPETITIVE HEATMAP: GIARDIASIS TREATMENT MARKET
  • FIGURE 28. Top player positioning, 2022
  • FIGURE 29. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. TEVA PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. TEVA PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. TEVA PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. BAXTER INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. BAXTER INTERNATIONAL INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. BAXTER INTERNATIONAL INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. ZYDUS PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. ZYDUS PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. ZYDUS PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. ROXANE LABORATORIES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. ROXANE LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. ROXANE LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. HERITAGE PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. HERITAGE PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. HERITAGE PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. AUROBINDO PHARMA LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. AUROBINDO PHARMA LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. AUROBINDO PHARMA LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. LUPIN PHARMACEUTICALS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. LUPIN PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. LUPIN PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. F. HOFFMANN-LA ROCHE LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Giardiasis Treatment Market

Start reading.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers